• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

突变 bla 基因表达和拷贝数增加导致肺炎克雷伯菌对头孢他啶/阿维巴坦高水平耐药。

Increased gene expression and copy number of mutated bla lead to high-level ceftazidime/avibactam resistance in Klebsiella pneumoniae.

机构信息

National Clinical Research Center for Respiratory Diseases, China-Japan Friendship Hospital, Capital Medical University, Beijing, China.

Laboratory of Clinical Microbiology and Infectious Diseases, Department of Pulmonary and Critical Care Medicine, Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing, China.

出版信息

BMC Microbiol. 2021 Aug 19;21(1):230. doi: 10.1186/s12866-021-02293-0.

DOI:10.1186/s12866-021-02293-0
PMID:34412588
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8375111/
Abstract

BACKGROUND

Resistance to ceftazidime-avibactam was reported, and it is important to investigate the mechanisms of ceftazidime/avibactam resistance in K. pneumoniae with mutations in bla.

RESULTS

We report the mutated bla is not the only mechanism related to CZA resistance, and investigate the role of outer porin defects, efflux pump, and relative gene expression and copy number of bla and ompk35/36. Four ceftazidime/avibactam-sensitive isolates detected wild type bla, while 4 ceftazidime/avibactam-resistant isolates detected mutated bla (bla, bla, and bla). Compared with other ceftazidime/avibactam-resistant isolates with the minimal inhibitory concentration of ceftazidime/avibactam ranging 128-256 mg/L, the relative gene expression and copy number of bla was increased in the isolate which carried bla and also showed the highest minimal inhibitory concentration of ceftazidime/avibactam at 2048 mg/L. The truncated Ompk35 contributes rare to ceftazidime/avibactam resistance in our isolates. No significant difference in minimal inhibitory concentration of ceftazidime/avibactam was observed after the addition of PABN.

CONCLUSIONS

Increased gene expression and copy number of mutated bla can cause high-level ceftazidime/avibactam resistance.

摘要

背景

已有报道称对头孢他啶-阿维巴坦产生耐药,因此有必要研究肺炎克雷伯菌中 bla 基因突变与头孢他啶/阿维巴坦耐药的相关机制。

结果

我们报告称 bla 的突变并非唯一与 CZA 耐药相关的机制,并研究了外孔蛋白缺陷、外排泵以及 bla 和 ompk35/36 的相对基因表达和拷贝数的作用。4 株头孢他啶/阿维巴坦敏感分离株检测到 bla 为野生型,而 4 株头孢他啶/阿维巴坦耐药分离株检测到 bla 发生突变(bla、bla 和 bla)。与其他头孢他啶/阿维巴坦耐药分离株(头孢他啶/阿维巴坦的最小抑菌浓度范围为 128-256 mg/L)相比,携带 bla 的分离株的 bla 相对基因表达和拷贝数增加,且其头孢他啶/阿维巴坦的最小抑菌浓度最高,达到 2048 mg/L。在我们的分离株中,截短的 Ompk35 对头孢他啶/阿维巴坦耐药的贡献很少。加入 PABN 后,头孢他啶/阿维巴坦的最小抑菌浓度没有显著差异。

结论

突变 bla 的基因表达和拷贝数增加可导致高水平的头孢他啶/阿维巴坦耐药。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcc7/8375111/b2f7bfb1eb60/12866_2021_2293_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcc7/8375111/96fd91105a4a/12866_2021_2293_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcc7/8375111/44adabbdf621/12866_2021_2293_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcc7/8375111/9a90ba6a7078/12866_2021_2293_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcc7/8375111/c805414f4f5d/12866_2021_2293_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcc7/8375111/b2f7bfb1eb60/12866_2021_2293_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcc7/8375111/96fd91105a4a/12866_2021_2293_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcc7/8375111/44adabbdf621/12866_2021_2293_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcc7/8375111/9a90ba6a7078/12866_2021_2293_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcc7/8375111/c805414f4f5d/12866_2021_2293_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bcc7/8375111/b2f7bfb1eb60/12866_2021_2293_Fig5_HTML.jpg

相似文献

1
Increased gene expression and copy number of mutated bla lead to high-level ceftazidime/avibactam resistance in Klebsiella pneumoniae.突变 bla 基因表达和拷贝数增加导致肺炎克雷伯菌对头孢他啶/阿维巴坦高水平耐药。
BMC Microbiol. 2021 Aug 19;21(1):230. doi: 10.1186/s12866-021-02293-0.
2
Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China.中国耐碳青霉烯类肺炎克雷伯菌中头孢他啶/阿维巴坦耐药的出现。
Clin Microbiol Infect. 2020 Jan;26(1):124.e1-124.e4. doi: 10.1016/j.cmi.2019.08.020. Epub 2019 Sep 5.
3
Molecular analysis of clinical isolates of ceftazidime-avibactam-resistant Klebsiella pneumoniae.头孢他啶-阿维巴坦耐药肺炎克雷伯菌临床分离株的分子分析。
Clin Microbiol Infect. 2021 Jul;27(7):1040.e1-1040.e6. doi: 10.1016/j.cmi.2021.03.001. Epub 2021 Mar 26.
4
Genomic characterization of a KPC-23-producing Klebsiella pneumoniae ST258 clinical isolate resistant to ceftazidime-avibactam.产 KPC-23 肺炎克雷伯菌 ST258 临床分离株对头孢他啶-阿维巴坦耐药的基因组特征。
Clin Microbiol Infect. 2019 Jun;25(6):763.e5-763.e8. doi: 10.1016/j.cmi.2019.03.011. Epub 2019 Mar 28.
5
Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections.耐碳青霉烯类肺炎克雷伯菌感染治疗期间因质粒介导的突变导致头孢他啶-阿维巴坦耐药的出现
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.02097-16. Print 2017 Mar.
6
Molecular Mechanisms Driving the Development of KPC-71-Mediated Resistance to Ceftazidime-Avibactam during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections.KPC-71 介导的对头孢他啶-阿维巴坦耐药性发展的分子机制在治疗碳青霉烯类耐药肺炎克雷伯菌感染中的作用。
mSphere. 2021 Dec 22;6(6):e0085921. doi: 10.1128/mSphere.00859-21.
7
Successive Emergence of Ceftazidime-Avibactam Resistance through Distinct Genomic Adaptations in -Harboring Klebsiella pneumoniae Sequence Type 307 Isolates.携带blaKPC-2 的肺炎克雷伯菌序列型 307 分离株通过不同的基因组适应性连续出现头孢他啶-阿维巴坦耐药性。
Antimicrob Agents Chemother. 2018 Feb 23;62(3). doi: 10.1128/AAC.02101-17. Print 2018 Mar.
8
Bloodstream infection caused by KPC-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam: epidemiology and genomic characterization.产碳青霉烯酶肺炎克雷伯菌引起的对头孢他啶/阿维巴坦耐药的血流感染:流行病学与基因组特征。
Clin Microbiol Infect. 2020 Apr;26(4):516.e1-516.e4. doi: 10.1016/j.cmi.2019.11.011. Epub 2019 Nov 16.
9
Molecular mechanisms responsible KPC-135-mediated resistance to ceftazidime-avibactam in ST11-K47 hypervirulent .ST11-K47 超毒力株中 KPC-135 介导的对头孢他啶-阿维巴坦耐药的分子机制。
Emerg Microbes Infect. 2024 Dec;13(1):2361007. doi: 10.1080/22221751.2024.2361007. Epub 2024 Jun 12.
10
In vitro mimicry of in vivo KPC mutations by ceftazidime-avibactam: phenotypes, mechanisms, genetic structure and kinetics of enzymatic hydrolysis.头孢他啶-阿维巴坦体外模拟体内 KPC 突变:表型、机制、酶水解的遗传结构和动力学。
Emerg Microbes Infect. 2024 Dec;13(1):2356146. doi: 10.1080/22221751.2024.2356146. Epub 2024 Jun 4.

引用本文的文献

1
Comparison of the in vitro activities and resistance mechanisms against imipenem-relebactam and ceftazidime-avibactam in clinical KPC-producing Klebsiella pneumoniae isolated in China.中国分离的产KPC肺炎克雷伯菌对亚胺培南-瑞来巴坦和头孢他啶-阿维巴坦的体外活性及耐药机制比较
Infection. 2025 Feb 15. doi: 10.1007/s15010-025-02474-3.
2
Evolution of ceftazidime-avibactam resistance driven by mutations in double-copy to during treatment of ST11 carbapenem-resistant .治疗 ST11 碳青霉烯类耐药肠杆菌科细菌时,由于双拷贝到的突变导致头孢他啶-阿维巴坦耐药性的进化。
mSystems. 2024 Oct 22;9(10):e0072224. doi: 10.1128/msystems.00722-24. Epub 2024 Sep 17.
3

本文引用的文献

1
KPC-53, a KPC-3 Variant of Clinical Origin Associated with Reduced Susceptibility to Ceftazidime-Avibactam.KPC-53,一种源自临床的KPC-3变体,对头孢他啶-阿维巴坦敏感性降低。
Antimicrob Agents Chemother. 2020 Dec 16;65(1). doi: 10.1128/AAC.01429-20.
2
Emergence of ceftazidime-avibactam resistance through distinct genomic adaptations in KPC-2-producing Klebsiella pneumoniae of sequence type 39 during treatment.在治疗期间,通过序列类型39的产KPC-2肺炎克雷伯菌中不同的基因组适应性变化出现了对头孢他啶-阿维巴坦的耐药性。
Eur J Clin Microbiol Infect Dis. 2021 Jan;40(1):219-224. doi: 10.1007/s10096-020-04000-9. Epub 2020 Jul 30.
3
TolC contributes to antimicrobial resistance, exopolysaccharide production, and virulence.
托尔克(TolC)有助于抗菌药物耐药性、胞外多糖产生和毒力。
Infect Immun. 2023 Dec 12;91(12):e0030323. doi: 10.1128/iai.00303-23. Epub 2023 Nov 20.
4
A Whole-Genome Sequencing-Based Approach for the Characterization of Co-Producing KPC and OXA-48-like Carbapenemases Circulating in Sardinia, Italy.一种基于全基因组测序的方法,用于鉴定在意大利撒丁岛传播的同时产生KPC和OXA-48样碳青霉烯酶的菌株特征。
Microorganisms. 2023 Sep 20;11(9):2354. doi: 10.3390/microorganisms11092354.
5
Clinical Characteristics and Outcome of Ceftazidime/Avibactam-Resistant Carbapenemase-Producing Infections: A Retrospective, Observational, 2-Center Clinical Study.产碳青霉烯酶的头孢他啶/阿维巴坦耐药感染的临床特征及转归:一项回顾性、观察性、双中心临床研究
Open Forum Infect Dis. 2023 Jun 30;10(7):ofad327. doi: 10.1093/ofid/ofad327. eCollection 2023 Jul.
6
What to Do with the New Antibiotics?如何应对新型抗生素?
Antibiotics (Basel). 2023 Mar 27;12(4):654. doi: 10.3390/antibiotics12040654.
7
adaptive antimicrobial resistance in during antibiotic therapy.抗生素治疗期间的适应性抗菌耐药性。
Front Microbiol. 2023 Mar 16;14:1159912. doi: 10.3389/fmicb.2023.1159912. eCollection 2023.
8
Genomic Analysis Revealed the International and Domestic Transmission of Carbapenem-Resistant in Chinese Pediatric Patients.基因组分析揭示了中国儿科患者中耐碳青霉烯类细菌的国际和国内传播情况。
Microbiol Spectr. 2023 Mar 1;11(2):e0321322. doi: 10.1128/spectrum.03213-22.
9
Emergence of Ceftazidime-Avibactam Resistance and Decreased Virulence in Carbapenem-Resistant ST11 During Antibiotics Treatment.抗生素治疗期间,耐碳青霉烯类 ST11 菌株中头孢他啶-阿维巴坦耐药性的出现及毒力降低
Infect Drug Resist. 2022 Nov 28;15:6881-6891. doi: 10.2147/IDR.S387187. eCollection 2022.
10
Multiple Copies of Mobile Tigecycline Resistance Efflux Pump Gene Cluster Identified in Chromosome of spp.多种移动替加环素耐药外排泵基因簇在 spp. 染色体中被鉴定
Microbiol Spectr. 2022 Dec 21;10(6):e0346822. doi: 10.1128/spectrum.03468-22. Epub 2022 Nov 10.
Phenotypic and genotypic analysis of KPC-51 and KPC-52, two novel KPC-2 variants conferring resistance to ceftazidime/avibactam in the KPC-producing Klebsiella pneumoniae ST11 clone background.
KPC-51和KPC-52的表型和基因型分析,这两种新型KPC-2变体在产KPC的肺炎克雷伯菌ST11克隆背景下赋予对头孢他啶/阿维巴坦的耐药性。
J Antimicrob Chemother. 2020 Oct 1;75(10):3072-3074. doi: 10.1093/jac/dkaa241.
4
Reduced Ceftazidime-Avibactam Susceptibility in KPC-Producing From Patients Without Ceftazidime-Avibactam Use History - A Multicenter Study in China.中国一项多中心研究:既往无头孢他啶-阿维巴坦使用史的产KPC菌株对头孢他啶-阿维巴坦的敏感性降低
Front Microbiol. 2020 Jun 23;11:1365. doi: 10.3389/fmicb.2020.01365. eCollection 2020.
5
Clinical outcomes of ceftazidime-avibactam in lung transplant recipients with infections caused by extensively drug-resistant gram-negative bacilli.头孢他啶-阿维巴坦治疗广泛耐药革兰阴性杆菌感染的肺移植受者的临床结局
Ann Transl Med. 2020 Feb;8(3):39. doi: 10.21037/atm.2019.10.40.
6
Ceftazidime-Avibactam Resistance Associated with Increased Gene Copy Number Mediated by pKpQIL Plasmid Derivatives in Sequence Type 258 .头孢他啶-阿维巴坦耐药与 258 型序列型中由 pKpQIL 质粒衍生物介导的基因拷贝数增加有关。
Antimicrob Agents Chemother. 2020 Mar 24;64(4). doi: 10.1128/AAC.01816-19.
7
Use of carbapenems in the combined treatment of emerging ceftazidime/avibactam-resistant and carbapenem-susceptible KPC-producing Klebsiella pneumoniae infections: Report of a case and review of the literature.碳青霉烯类药物联合治疗新出现的头孢他啶/阿维巴坦耐药和碳青霉烯类敏感产 KPC 肺炎克雷伯菌感染的应用:1 例病例报告及文献复习。
J Glob Antimicrob Resist. 2020 Sep;22:9-12. doi: 10.1016/j.jgar.2019.11.007. Epub 2019 Nov 13.
8
Genomic characterization of a Klebsiella pneumoniae ST1519 resistant to ceftazidime/avibactam carrying a novel KPC variant (KPC-36).一株携带新型KPC变体(KPC-36)的对头孢他啶/阿维巴坦耐药的肺炎克雷伯菌ST1519的基因组特征分析
Int J Antimicrob Agents. 2020 Jan;55(1):105816. doi: 10.1016/j.ijantimicag.2019.09.020. Epub 2019 Oct 5.
9
Phenotypic, biochemical and genetic analysis of KPC-41, a KPC-3 variant conferring resistance to ceftazidime-avibactam and exhibiting reduced carbapenemase activity.KPC-41的表型、生化和遗传分析,KPC-41是KPC-3的一种变体,对头孢他啶-阿维巴坦耐药且碳青霉烯酶活性降低。
Antimicrob Agents Chemother. 2019 Sep 9;63(12). doi: 10.1128/AAC.01111-19. Epub 2019 Sep 16.
10
Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China.中国耐碳青霉烯类肺炎克雷伯菌中头孢他啶/阿维巴坦耐药的出现。
Clin Microbiol Infect. 2020 Jan;26(1):124.e1-124.e4. doi: 10.1016/j.cmi.2019.08.020. Epub 2019 Sep 5.